| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $61,678,655 | 30 | 79 |
Sells | $1,548,339 | 8 | 21 |
| AKKARAJU SRINIVAS | director | 15 | $29.8M | 1 | $1.01M | $28.78M |
| Foresite Capital Management VI LLC | 10 percent owner | 5 | $10.63M | 0 | $0 | $10.63M |
| Foresite Labs, LLC | 10 percent owner | 5 | $10.63M | 0 | $0 | $10.63M |
| Tananbaum James B. | 5 | $10.63M | 0 | $0 | $10.63M | |
| Drappa Jorn | Chief Medical Officer | 0 | $0 | 1 | $64,527 | $-64,527 |
| Bradley Mark Christopher | Chief Development Officer | 0 | $0 | 1 | $67,824 | $-67,824 |
| Goldstein David M | Chief Scientific Officer | 0 | $0 | 1 | $68,457 | $-68,457 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr | 0 | $0 | 1 | $70,988 | $-70,988 |
| Schroer John R. | Chief Financial Officer | 0 | $0 | 1 | $86,546 | $-86,546 |
| Pangali Sanam | Chief Legal Officer | 0 | $0 | 2 | $175,969 | $-175,969 |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid …
Over the last 12 months, insiders at Alumis Inc. have bought $61.68M and sold $1.55M worth of Alumis Inc. stock.
On average, over the past 5 years, insiders at Alumis Inc. have bought $32M and sold $1.55M worth of stock each year.
Highest buying activity among insiders over the last 12 months: AKKARAJU SRINIVAS (director) — $29.8M. Foresite Capital Management VI LLC (10 percent owner) — $10.63M. Foresite Labs, LLC (10 percent owner) — $10.63M.
The last purchase of 546,581 shares for transaction amount of $5.81M was made by AKKARAJU SRINIVAS (director) on 2026‑09‑08.
| 2026-09-08 | Sale | AKKARAJU SRINIVAS | director | 96,131 0.0751% | $10.55 | $1.01M | -33.70% | |
| 2026-09-08 | AKKARAJU SRINIVAS | director | 546,581 0.43% | $10.63 | $5.81M | -33.70% | ||
| 2026-09-04 | AKKARAJU SRINIVAS | director | 440,140 0.347% | $11.17 | $4.92M | -36.40% | ||
| 2026-08-03 | Sale | Hardiman Roy C. | Chief Business & Strategy Ofcr | 2,692 0.0022% | $26.37 | $70,988 | -69.75% | |
| 2026-08-03 | Sale | Drappa Jorn | Chief Medical Officer | 2,447 0.002% | $26.37 | $64,527 | -69.75% | |
| 2026-08-03 | Sale | Bradley Mark Christopher | Chief Development Officer | 2,572 0.0021% | $26.37 | $67,824 | -69.75% | |
| 2026-08-03 | Sale | Goldstein David M | Chief Scientific Officer | 2,596 0.0021% | $26.37 | $68,457 | -69.75% | |
| 2026-08-03 | Sale | Schroer John R. | Chief Financial Officer | 3,282 0.0026% | $26.37 | $86,546 | -69.75% | |
| 2026-08-03 | Sale | Pangali Sanam | Chief Legal Officer | 1,364 0.0011% | $26.37 | $35,969 | -69.75% | |
| 2026-07-06 | Sale | Pangali Sanam | Chief Legal Officer | 5,000 0.0042% | $28.00 | $140,000 | -61.20% | |
| 2026-01-09 | AKKARAJU SRINIVAS | director | 588,235 0.4897% | $17.00 | $10M | +24.44% | ||
| 2026-01-08 | Tananbaum James B. | 411,764 0.3688% | $17.00 | $7M | +33.42% | |||
| 2026-01-08 | Foresite Labs, LLC | 10 percent owner | 411,764 0.3688% | $17.00 | $7M | +33.42% | ||
| 2026-01-08 | Foresite Capital Management VI LLC | 10 percent owner | 411,764 0.3688% | $17.00 | $7M | +33.42% | ||
| 2025-12-05 | AKKARAJU SRINIVAS | director | 186,377 0.0992% | $9.84 | $1.83M | +112.59% | ||
| 2025-12-04 | AKKARAJU SRINIVAS | director | 66,027 0.0292% | $8.18 | $540,101 | +184.58% | ||
| 2025-12-03 | AKKARAJU SRINIVAS | director | 100,000 0.0419% | $7.75 | $775,000 | +200.57% | ||
| 2025-12-02 | AKKARAJU SRINIVAS | director | 96,000 0.0392% | $7.55 | $724,800 | +217.27% | ||
| 2025-12-01 | AKKARAJU SRINIVAS | director | 86,350 0.0348% | $7.46 | $644,171 | +219.18% | ||
| 2025-11-28 | AKKARAJU SRINIVAS | director | 38,702 0.016% | $7.64 | $295,683 | +205.22% |
| Tananbaum James B. | 5702536 4.4057% | $37.07M | 7 | 0 | +14.42% | |
| Foresite Capital Management VI LLC | 10 percent owner | 5702536 4.4057% | $37.07M | 7 | 0 | +14.42% |
| Foresite Labs, LLC | 10 percent owner | 5702536 4.4057% | $37.07M | 7 | 0 | +14.42% |
| AKKARAJU SRINIVAS | director | 4937026 3.8143% | $32.09M | 17 | 1 | +11.58% |
| Babler Martin | President, CEO and Chairman | 106454 0.0822% | $691,951.00 | 1 | 0 | <0.0001% |
| Colowick Alan | director | 18404 0.0142% | $119,626.00 | 2 | 0 | <0.0001% |
$100,473,344 | 83 | 9.53% | $826.91M | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$11,663,618 | 57 | 32.20% | $934.29M |
| Increased Positions | 78 | +56.12% | 15M | +19.34% |
| Decreased Positions | 58 | -41.73% | 13M | -16.16% |
| New Positions | 30 | New | 10M | New |
| Sold Out Positions | 26 | Sold Out | 8M | Sold Out |
| Total Postitions | 159 | +14.39% | 80M | +3.18% |